TIDMYGEN

RNS Number : 4934Z

Yourgene Health PLC

21 May 2021

Yourgene Health plc

("Yourgene" or the "Company")

Director / PDMR Shareholding

Manchester, UK - 21 May 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified on 21 May 2021 that Dr Bill Chang, a Director of the Company, transferred his entire shareholding on 21 May 2021, consisting of 80,000,142 ordinary shares in the Company, from his personal account to Changsform Innovations Pte. Ltd., a company wholly owned by Dr Bill Chang.

Dr Bill Chang's interest in the Company remains unchanged, representing 11.1 per cent of the Company's issued share capital.

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                    Dr Bill Chang 
      --------------------------------------  ----------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status                         Director 
      --------------------------------------  ----------------------------------- 
 b)    Initial notification                    Initial notification 
        /Amendment 
      --------------------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                    Yourgene Health plc 
      --------------------------------------  ----------------------------------- 
 b)    LEI                                     213800UUIT8BZE7QEH33 
      --------------------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the                      Ordinary shares of 0.1p each 
        financial instrument, 
        type of instrument 
 
       Identification code                     ISIN: GB00BN31ZD89 
 
 b)    Nature of the transaction               Transfer of shares 
      --------------------------------------  ----------------------------------- 
 c)    Price(s) and volume(s) 
                                               ---------------  --------------- 
                                                Price(s)         Volume(s) 
                                               ---------------  --------------- 
    n/a                                                          80,000,142 
   -----------------------------------------------------------  --------------- 
 
 d)    Aggregated information                  N/A 
 
  - Aggregated volume 
 
  - Price 
 
 e)    Date of the transaction                 21 May 2021 
      --------------------------------------  ----------------------------------- 
 f)    Place of the transaction                Singapore 
      --------------------------------------  ----------------------------------- 
 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                  Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                              investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                 Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
 
N+1 Singer (Joint Corporate Broker)                                  Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor       Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                           Mob: 07980 541 893 / Mob: 07584 391 
                                                                                          303 
 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEFLFLFELLBBD

(END) Dow Jones Newswires

May 21, 2021 11:30 ET (15:30 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Yourgene Health Charts.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Yourgene Health Charts.